Shire PLC (SHP) Stock Rating Reaffirmed by Liberum Capital
Shire PLC (LON:SHP)‘s stock had its “buy” rating reaffirmed by equities research analysts at Liberum Capital in a research note issued to investors on Monday. They presently have a GBX 4,200 ($55.24) price target on the biopharmaceutical company’s stock. Liberum Capital’s price target points to a potential upside of 14.18% from the company’s previous close.
A number of other research analysts have also recently issued reports on the company. Kepler Capital Markets reissued a “buy” rating and issued a GBX 4,600 ($60.50) target price on shares of Shire PLC in a research note on Friday. Royal Bank Of Canada reissued an “outperform” rating on shares of Shire PLC in a research note on Friday. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research note on Monday, November 13th. Berenberg Bank boosted their target price on Shire PLC from GBX 5,900 ($77.60) to GBX 6,000 ($78.92) and gave the company a “buy” rating in a research note on Monday, November 6th. Finally, Deutsche Bank AG decreased their target price on Shire PLC from GBX 5,700 ($74.97) to GBX 5,500 ($72.34) and set a “buy” rating for the company in a research note on Wednesday, November 1st. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of GBX 5,358.82 ($70.48).
Shire PLC (SHP) opened at GBX 3,678.50 ($48.38) on Monday. Shire PLC has a 52 week low of GBX 3,435.50 ($45.19) and a 52 week high of GBX 5,067 ($66.64).
ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/20/shire-plc-shp-stock-rating-reaffirmed-by-liberum-capital.html.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.